Jun Wei from San Diego, CA, age 62

Professional Records

Lawyers & Attorneys

Jun Wei - Lawyer

View page

Office:

Hogan Lovells International LLP

Specialties:

Corporate
Intellectual Property
Patents
Communications and Media
Private Equity/Venture Capital
Infrastructure and Project Finance
International Arbitration
Climate Change
Finance
International Trade and Investment
Bribery, Corruption and Foreign Corrupt Practices Act Investigations

ISLN:

902897180

Admitted:

1979

Law School:

Beijing University, LL.B., 1977; Beijing University, LL.M., 1981; Harvard Law School, LL.M., 1990

Medicine Doctors

Jun Wei

View page

Specialties:

Internal Medicine

Resumes

Global Architect - Collaboration Infrastructure

View page

Location:

Buffalo, New York

Industry:

Information Technology and Services

Skills:

SharePoint
Intranet
Enterprise Architecture
IT Strategy
Messaging

Languages:

Chinese

Scientist

View page

Location:

San Diego, CA

Industry:

Pharmaceuticals

Work:

Sanford Burnham Prebys Medical Discovery Institute Apr 2010 - Jul 2013
Scientist
Amphastar Pharmaceuticals, Inc. Apr 2010 - Jul 2013
Scientist
Sanford Burnham Prebys Medical Discovery Institute Apr 2007 - Apr 2010
Post-Doctoral Fellow
University of New Mexico Aug 2001 - Apr 2007
Ph.d

Education:

The University of New Mexico 2001 - 2007
Doctorates, Doctor of Philosophy, Organic Chemistry Northwestern Polytechnical University 1998 - 2001

Skills:

Organic Synthesis
Organic Chemistry
Nmr
Cancer
Medicinal Chemistry
Lead Optimization
Drug Discovery
Peptide Synthesis
Biochemistry
Protein Chemistry
Hplc
Life Sciences
Biotechnology
Cell Culture
Lc Ms
High Throughput Screening
Drug Design
Chemistry
Purification
Molecular Biology
Formulation
Drug Development

Languages:

English
Mandarin

Jun Wei

View page

Location:

Greater San Diego Area

Industry:

Chemicals

Jun Wei San Diego, CA

View page

Work:

Sanford Burnham Medical Research Institute

May 2010 to 2000
Scientist
University of New Mexico
Albuquerque, NM
Aug 2001 to Apr 2007
Teaching Asistant

Education:

Sanford Burnham Medical Research Institute
San Diego, CA
Jan 2007 to Jan 2010
Postdoc in Medicinal Chemistry
University of new Mexico
Albuquerque, NM
Jan 2001 to Jan 2007
PH.D. in Organic Chemistry
Northwestern Polytechnical University
xian
Jan 1998 to Jan 2001
M.S. in Physical Chemistry

Skills:

Organic and Medicinal Chemistry. 1. Natural product synthesis. 2. Design and perform multi-step synthese (1-20 steps). 3.Quickly convert hits to a lead. 4. Lead optimization 5. Fragment-based Drug discovery . 5. Experience with 1D, 2D-NMR, LC-MS, GC-MS, HPLC, IR.

Publications

Us Patents

Apogossypolone Derivatives As Anticancer Agents

View page

US Patent:

20110112112, May 12, 2011

Filed:

Oct 7, 2010

Appl. No.:

12/900378

Inventors:

Maurizio Pellecchia - La Jolla CA, US
Jun Wei - La Jolla CA, US

Assignee:

Sanford-Burnham Medical Research Institute - La Jolla CA

International Classification:

A61K 31/496
G01N 33/48
C12N 5/071
A61K 31/135
A61K 31/137
A61K 31/343
A61K 31/497
A61K 31/122
A61K 31/16
C12N 5/09
A61P 25/28
A61P 37/02
A61P 25/00
A61P 25/24
A61P 35/00

US Classification:

51425215, 436 86, 436 94, 435325, 514647, 514651, 514462, 51425304, 514680, 514613

Abstract:

The disclosure provides compounds and methods of using Apogossypolone derivatives for treating diseases and disorders. In particular, the disclosure provides compounds of Formula I:or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and provides methods for the preparation of compounds of Formula I; and methods for treating cancer, autoimmune diseases, and inflammation by administering a compound of Formula I.

Inhibitors Of Cancer Invasion, Attachment, And/Or Metastasis

View page

US Patent:

20210214365, Jul 15, 2021

Filed:

Jan 14, 2021

Appl. No.:

17/148813

Inventors:

- Richmond VA, US
- La Jolla CA, US
Swadesh K. DAS - Richmond VA, US
Timothy P. KEGELMAN - Richmond VA, US
Bainan WU - Richmond VA, US
Surya K. DE - Richmond VA, US
Jun WEI - La Jolla CA, US
Mitchell E. MENEZES - Richmond VA, US
Luni EMDAD - Richmond VA, US

International Classification:

C07D 487/04
A61P 35/04
A61K 31/519
A61K 45/06
C07D 495/14

Abstract:

Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.